Opinion|Videos|December 11, 2024
Hyperkalemia and Heart Failure Insights
Author(s)Orly Vardeny, PharmD, MS
A panelist discusses how the FINEARTS-HF trial employed rigorous potassium-monitoring protocols and predefined hyperkalemia thresholds to evaluate finerenone's safety profile in patients with heart failure (HF), revealing important associations between baseline characteristics and hyperkalemia risk while demonstrating the drug's complex effects on potassium homeostasis.
Advertisement
Video content above is prompted by the following:
- What methodological considerations and unique insights emerged from the FINEARTS-HF trial's investigation of hyperkalemia risk, and how did the study design address the relationship between potassium levels and clinical outcomes?
- What baseline characteristics were associated with a higher risk of developing hyperkalemia in the FINEARTS-HF trial, and how might these findings inform the management of patients with HF?
- How did the impact of finerenone on potassium levels and hyperkalemia-related outco-mes differ from placebo, and what are the implications for its clinical use in patients with heart failure?
Advertisement
Related to this article
Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
3
Acoramidis Linked to Fewer Hospitalizations Than Tafamidis in ATTR-CM
4
Disease Extent Linked to Complications After Deep Endometriosis Surgery
5